Neko Health just raised $700 million and, according to the report, is now valued at about $7 billion. That scale matters because body-scanning is not a “nice-to-have” science project. It is a bet on turning measurement into care, and care into a repeatable business people will actually pay for.

The timing also matters. Neko Health is heading to New York, and it is doing so with visible, high-profile support from Mark Zuckerberg, Maria Sharapova, and will.i.am. For founders, investors, and operators watching health tech, the message is clear: the company is trying to move from “promising demo” into “real distribution,” and New York is a loud, competitive market that forces product maturity fast.

So how does a $700M raise connect to a very specific, human story? The company points to its market strategy: “We’ve gone into markets where health care is free, and hundreds of thousands of people line up in a queue” to pay for it. Put simply, the startup is arguing that when health care costs are not the barrier, demand still shows up. That is a powerful incentive signal for any category trying to sell measurement, diagnostics, or proactive wellness experiences. If people will queue and pay even where they can get care without a bill, the next question becomes whether the scanning results are trusted enough to justify the transaction every time.

There is also a regulatory and operational subtext lurking behind that one sentence. Health care is free in some places, but that does not mean “anything medical goes.” Any body-scanning company has to navigate how results are classified, how claims are framed, and how outcomes are validated. The funding itself does not remove those constraints. It changes the runway and the leverage: more capital means more time to run studies, more capacity to iterate on device accuracy and workflow, and more ability to staff compliance and partnerships. In a state like New York, where healthcare ecosystems are dense and scrutiny is common, the operational burden can be higher. That is exactly why moving there after raising $700M reads like an execution decision, not a brand decision.

Now zoom out to the board dynamics and investor signaling. Neko Health is backed by names that are not only famous, but influential across tech and culture: Mark Zuckerberg, Maria Sharapova, and will.i.am. When that kind of roster attaches to a health-related company, it tends to do two things. First, it helps the company attract talent and partners because people assume the business has more staying power. Second, it compresses the credibility timeline. You are not starting from zero, so you get to push faster into partnerships, pilots, and distribution. For the executives involved, it also raises the expectation ceiling: stakeholders will want visible progress, not vague “potential.”

Why does that matter for decision-makers beyond Neko Health? Because the category has a recurring pattern: plenty of sensors and software can measure. Fewer companies can convert measurement into regular behavior, consistent revenue, and defensible positioning versus established healthcare workflows. A $700M round at about $7B valuation suggests investors are betting that Neko Health can do that conversion. That creates pressure on peers to show the same kind of demand evidence, not just technical capability.

It also reframes the go-to-market playbook. The company’s “free healthcare markets” approach is a way to avoid hiding behind price sensitivity. If people pay anyway, the business can argue that value is perceived, not merely purchased out of necessity. That should influence how competitors structure pricing, partnerships, and messaging. It also puts more focus on where scanning happens, who it is for, and what the user experience looks like from queue to follow-up. In health tech, the product is often the easy part. The funnel is the hard part.

Finally, consider what “heading to New York” means as a strategic stakes move. New York is not just another city. It is a market where healthcare providers, regulators, and consumer attention all collide. For Neko Health’s executives and investors, the risk is obvious: scaling in a complex environment can surface constraints quickly. But the potential upside is also obvious: if the company can operate there successfully after raising $700M, it becomes harder for skeptics to dismiss body-scanning as a niche curiosity.

In other words, the raise and the New York plan are one story. The funding provides the resources to scale operations and validate claims. The queue anecdote provides the demand story. Put them together and you get a clear bet: body-scanning can move from laboratory promise into mainstream paid usage, and it is starting in one of the toughest places to do it.